key: cord-1024468-59g623nv
authors: Rouzé, Anahita; Saura, Ouriel; Nseir, Saad
title: High Incidence of Nosocomial Infections in COVID-19 Patients: Is SARS-CoV-2 the Culprit?
date: 2021-09-03
journal: Chest
DOI: 10.1016/j.chest.2021.04.074
sha: e19c155245a1e983d4bea1cc4e96c4662ddff5a6
doc_id: 1024468
cord_uid: 59g623nv

nan

Editor's Note: Authors are invited to respond to Correspondence that cites their previously published work. Those responses appear after the related letter. In cases where there is no response, the author of the original article declined to respond or did not reply to our invitation.

Is SARS-CoV-2 the Culprit?

To the Editor:

Grasselli et al 1 reported in CHEST (August 2021) the results of a retrospective multicenter study aiming to determine the incidence and microbiology of hospitalacquired infections (HAI) in patients with COVID-19 who were hospitalized in the ICU. The incidence of HAI (46%) and ventilator-associated pneumonia (VAP) (50%) appears to be very high. However, as acknowledged by the authors, no comparison was performed with a control group, such as patients with influenza pneumonia or ARDS. Could the authors at least provide the incidence of HAI and VAP in the participating ICU before the pandemic? This would be helpful to estimate the potential effect of SARS-CoV-2 infection on the rate of these infections. Similarly, the incidence of multidrug-resistant bacteria is quite high. What was the incidence of these bacteria in the participating ICUs before the pandemic?

Our group recently reported the results of a large multicenter European study aiming to determine the impact of SARS-CoV-2 infection on the incidence of ventilator-associated lower respiratory tract infections (VALRTI) (ie, VAP and ventilator-associated tracheobronchitis). 2 Although the incidence of VALRTI was in line with that reported by the authors, 1 the incidence of multidrugresistant bacteria was lower in SARS-CoV-2 pneumonia, compared with the influenza and no viral infection groups (23%, 38%, and 34%, respectively).

No clear explanation is provided by Grasselli et al 1 for the high incidence of HAI and VAP in study patients. Is it related only to the long duration of ICU stay and mechanical ventilation in patients with COVID-19? Another potential explanation is the high incidence of ARDS in patients with COVID-19, because ARDS is a well-known risk factor for VAP. 3 Specific pulmonary lesions that result from SARS-CoV-2 infection and alteration of pulmonary and digestive microbiota might also participate in the pathogenesis of VAP and HAI in these patients. 4, 5 Further studies are needed to better explain the pathophysiologic condition of ICU-acquired infections in patients with COVID-19. 

Hospital-acquired infections in critically-ill COVID-19 patients

Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study

Pulmonary infections complicating ARDS

Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection

Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19